Nektar reports Q4 2022 net loss $59.7M; cash $505M, runway through mid-2025

NEKTAR THERAPEUTICS

2022-FY EPS reported -$1.97 revenue$92,055,000

Q4 2022 revenue $22.0M (down from $25.0M YoY); full-year revenue $92.1M (down from $101.9M).
Q4 net loss $59.7M ($0.32 loss per share) vs $145.6M ($0.79) in Q4 2021; full-year net loss $368.2M ($1.97) vs $523.8M ($2.86).
Cash and investments $505.0M at Dec 31, 2022, down from $798.8M; CEO expects runway through at least mid-2025 with additional cost cuts.
R&D expense fell to $34.7M in Q4 (from $99.6M) due to wind down of bempegaldesleukin program; restructuring costs $11.6M in Q4.
On Feb 23, 2023, announced Phase 2 topline data for rezpegaldesleukin in SLE; no Q4 earnings call held.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NEKTAR THERAPEUTICS reported the quarter and year ended December 31, 2022 results: revenue Revenue in the fourth quarter of 2022 was $22.0 million, net income Net loss for the fourth quarter of 2022 was $59.7 million, EPS $0.32 basic and diluted loss per share.

Period: the quarter and year ended December 31, 2022
Revenue: Revenue in the fourth quarter of 2022 was $22.0 million
Net income: Net loss for the fourth quarter of 2022 was $59.7 million
EPS: $0.32 basic and diluted loss per share
Result: reported results

Exact text from the filing

On February 28, 2023, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-23-015546

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.